-
1
-
-
84894486696
-
Nutrient regulation of the mTOR complex 1 signalling pathway
-
Kim S.G., Buel G.R., Blenis J. Nutrient regulation of the mTOR complex 1 signalling pathway. Mol Cells 2013, 35(6):463-473.
-
(2013)
Mol Cells
, vol.35
, Issue.6
, pp. 463-473
-
-
Kim, S.G.1
Buel, G.R.2
Blenis, J.3
-
2
-
-
44449161481
-
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth
-
Huang J., Manning B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008, 412(2):179-190.
-
(2008)
Biochem J
, vol.412
, Issue.2
, pp. 179-190
-
-
Huang, J.1
Manning, B.D.2
-
3
-
-
49149088555
-
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis
-
Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008, 14(8):843-848.
-
(2008)
Nat Med
, vol.14
, Issue.8
, pp. 843-848
-
-
Ehninger, D.1
Han, S.2
Shilyansky, C.3
Zhou, Y.4
Li, W.5
Kwiatkowski, D.J.6
-
4
-
-
49849090082
-
The mTOR pathway and its role in human genetic diseases
-
Rosner M., Hanneder M., Siegel N., Valli A., Fuchs C., Hengstschlager M., et al. The mTOR pathway and its role in human genetic diseases. Mutat Res 2008, 659(3):284-292.
-
(2008)
Mutat Res
, vol.659
, Issue.3
, pp. 284-292
-
-
Rosner, M.1
Hanneder, M.2
Siegel, N.3
Valli, A.4
Fuchs, C.5
Hengstschlager, M.6
-
5
-
-
84877965001
-
Regulation of mTORC1 and its impact on gene expression at a glance
-
Laplante M., Sabatini D.M. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci 2013, 126(Pt 8):1713-1719.
-
(2013)
J Cell Sci
, vol.126
, pp. 1713-1719
-
-
Laplante, M.1
Sabatini, D.M.2
-
6
-
-
79955779584
-
MTOR links oncogenic signaling to tumor cell metabolism
-
Yecies J.L., Manning B.D. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl) 2011, 89(3):221-228.
-
(2011)
J Mol Med (Berl)
, vol.89
, Issue.3
, pp. 221-228
-
-
Yecies, J.L.1
Manning, B.D.2
-
7
-
-
84894628256
-
Kinase mTOR: regulation and role in maintenance of cellular homeostasis, tumor development, and aging
-
Parkhitko A.A., et al. Kinase mTOR: regulation and role in maintenance of cellular homeostasis, tumor development, and aging. Biochemistry (Mosc) 2014, 79(2):88-101.
-
(2014)
Biochemistry (Mosc)
, vol.79
, Issue.2
, pp. 88-101
-
-
Parkhitko, A.A.1
-
8
-
-
82555166000
-
MTOR signaling in disease
-
Dazert E., Hall M.N. mTOR signaling in disease. Curr Opin Cell Biol 2011, 23(6):744-755.
-
(2011)
Curr Opin Cell Biol
, vol.23
, Issue.6
, pp. 744-755
-
-
Dazert, E.1
Hall, M.N.2
-
9
-
-
77949882117
-
The tuberous sclerosis complex
-
Orlova K.A., Crino P.B. The tuberous sclerosis complex. Ann N Y Acad Sci 2010, 1184:87-105.
-
(2010)
Ann N Y Acad Sci
, vol.1184
, pp. 87-105
-
-
Orlova, K.A.1
Crino, P.B.2
-
11
-
-
84912135993
-
Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies
-
Liu J., Reeves C., Michalak Z., Coppola A., Diehl B., Sisodiya S.M., et al. Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies. Acta Neuropathol Commun 2014, 2:71.
-
(2014)
Acta Neuropathol Commun
, vol.2
, pp. 71
-
-
Liu, J.1
Reeves, C.2
Michalak, Z.3
Coppola, A.4
Diehl, B.5
Sisodiya, S.M.6
-
12
-
-
84870873020
-
Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation
-
Prabowo A.S., Anink J.J., Lammens M., Nellist M., van den Ouweland A.M., Adle-Biassette H., et al. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. Brain Pathol 2013, 23(1):45-59.
-
(2013)
Brain Pathol
, vol.23
, Issue.1
, pp. 45-59
-
-
Prabowo, A.S.1
Anink, J.J.2
Lammens, M.3
Nellist, M.4
van den Ouweland, A.M.5
Adle-Biassette, H.6
-
13
-
-
84896320213
-
Fetal brain mTOR signaling activation in tuberous sclerosis complex
-
Tsai V., Parker W.E., Orlova K.A., Baybis M., Chi A.W., Berg B.D., et al. Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cereb Cortex 2014, 24(2):315-327.
-
(2014)
Cereb Cortex
, vol.24
, Issue.2
, pp. 315-327
-
-
Tsai, V.1
Parker, W.E.2
Orlova, K.A.3
Baybis, M.4
Chi, A.W.5
Berg, B.D.6
-
14
-
-
84872088946
-
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
-
Franz D.N., Belousova E., Sparagana S., Bebin E.M., Frost M., Kuperman R., et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013, 381(9861):125-132.
-
(2013)
Lancet
, vol.381
, Issue.9861
, pp. 125-132
-
-
Franz, D.N.1
Belousova, E.2
Sparagana, S.3
Bebin, E.M.4
Frost, M.5
Kuperman, R.6
-
15
-
-
84874746597
-
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
-
Bissler J.J., Kingswood J.C., Radzikowska E., Zonnenberg B.A., Frost M., Belousova E., et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013, 381(9869):817-824.
-
(2013)
Lancet
, vol.381
, Issue.9869
, pp. 817-824
-
-
Bissler, J.J.1
Kingswood, J.C.2
Radzikowska, E.3
Zonnenberg, B.A.4
Frost, M.5
Belousova, E.6
-
16
-
-
79955510505
-
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
-
McCormack F.X., Inoue Y., Moss J., Singer L.G., Strange C., Nakata K., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011, 364(17):1595-1606.
-
(2011)
N Engl J Med
, vol.364
, Issue.17
, pp. 1595-1606
-
-
McCormack, F.X.1
Inoue, Y.2
Moss, J.3
Singer, L.G.4
Strange, C.5
Nakata, K.6
-
17
-
-
84884511014
-
Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference
-
G. International Tuberous Sclerosis Complex Consensus
-
Krueger D.A., Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 2013, 49(4):255-265. G. International Tuberous Sclerosis Complex Consensus.
-
(2013)
Pediatr Neurol
, vol.49
, Issue.4
, pp. 255-265
-
-
Krueger, D.A.1
Northrup, H.2
-
18
-
-
84927171958
-
Renal tumours in a Tsc2 mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin
-
Online publication on 17 March 2014.
-
Yang J., Kalogerou M., Samsel P.A., Zhang Y., Griffiths D.F., Gallacher J., et al. Renal tumours in a Tsc2 mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin. Oncogene 2014, Online publication on 17 March 2014; doi: 10.1038/onc.2014.17.
-
(2014)
Oncogene
-
-
Yang, J.1
Kalogerou, M.2
Samsel, P.A.3
Zhang, Y.4
Griffiths, D.F.5
Gallacher, J.6
-
19
-
-
42949140259
-
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
-
Zeng L.H., Xu L., Gutmann D.H., Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63(4):444-453.
-
(2008)
Ann Neurol
, vol.63
, Issue.4
, pp. 444-453
-
-
Zeng, L.H.1
Xu, L.2
Gutmann, D.H.3
Wong, M.4
-
20
-
-
84890806945
-
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
-
Krueger D.A., Wilfong A.A., Holland-Bouley K., Anderson A.E., Agricola K., Tudor C., et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013, 74(5):679-687.
-
(2013)
Ann Neurol
, vol.74
, Issue.5
, pp. 679-687
-
-
Krueger, D.A.1
Wilfong, A.A.2
Holland-Bouley, K.3
Anderson, A.E.4
Agricola, K.5
Tudor, C.6
-
21
-
-
78049510428
-
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
-
Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363(19):1801-1811.
-
(2010)
N Engl J Med
, vol.363
, Issue.19
, pp. 1801-1811
-
-
Krueger, D.A.1
Care, M.M.2
Holland, K.3
Agricola, K.4
Tudor, C.5
Mangeshkar, P.6
-
22
-
-
79959262531
-
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial
-
Davies D.M., de Vries P.J., Johnson S.R., McCartney D.L., Cox J.A., Serra A.L., et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res: Off J Am Assoc Cancer Res 2011, 17(12):4071-4081.
-
(2011)
Clin Cancer Res: Off J Am Assoc Cancer Res
, vol.17
, Issue.12
, pp. 4071-4081
-
-
Davies, D.M.1
de Vries, P.J.2
Johnson, S.R.3
McCartney, D.L.4
Cox, J.A.5
Serra, A.L.6
-
23
-
-
38049177875
-
Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis
-
Davies D.M., Johnson S.R., Tattersfield A.E., Kingswood J.C., Cox J.A., McCartney D.L., et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008, 358(2):200-203.
-
(2008)
N Engl J Med
, vol.358
, Issue.2
, pp. 200-203
-
-
Davies, D.M.1
Johnson, S.R.2
Tattersfield, A.E.3
Kingswood, J.C.4
Cox, J.A.5
McCartney, D.L.6
-
24
-
-
84865371057
-
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1
-
Dibble C.C., Elis W., Menon S., Qin W., Klekota J., Asara J.M., et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell 2012, 47(4):535-546.
-
(2012)
Mol Cell
, vol.47
, Issue.4
, pp. 535-546
-
-
Dibble, C.C.1
Elis, W.2
Menon, S.3
Qin, W.4
Klekota, J.5
Asara, J.M.6
-
25
-
-
84890134229
-
Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly
-
Capo-Chichi J.M., Tcherkezian J., Hamdan F.F., Decarie J.C., Dobrzeniecka S., Patry L., et al. Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly. J Med Genet 2013, 50(11):740-744.
-
(2013)
J Med Genet
, vol.50
, Issue.11
, pp. 740-744
-
-
Capo-Chichi, J.M.1
Tcherkezian, J.2
Hamdan, F.F.3
Decarie, J.C.4
Dobrzeniecka, S.5
Patry, L.6
-
26
-
-
84896109407
-
TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease
-
Alfaiz A.A., Micale L., Mandriani B., Augello B., Pellico M.T., Chrast J., et al. TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease. Hum Mutat 2014, 35(4):447-451.
-
(2014)
Hum Mutat
, vol.35
, Issue.4
, pp. 447-451
-
-
Alfaiz, A.A.1
Micale, L.2
Mandriani, B.3
Augello, B.4
Pellico, M.T.5
Chrast, J.6
-
27
-
-
84873349273
-
Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis
-
Sarnat H., Flores-Sarnat L., Crino P., Hader W., Bello-Espinosa L. Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis. Folia Neuropathol 2012, 50(4):330-345.
-
(2012)
Folia Neuropathol
, vol.50
, Issue.4
, pp. 330-345
-
-
Sarnat, H.1
Flores-Sarnat, L.2
Crino, P.3
Hader, W.4
Bello-Espinosa, L.5
-
28
-
-
0029884689
-
Synaptogenesis in hemimegalencephaly: the numerical density of asymmetric and symmetric synapses in the cerebral cortex
-
O'Kusky J.R., Akers M.A., Vinters H.V. Synaptogenesis in hemimegalencephaly: the numerical density of asymmetric and symmetric synapses in the cerebral cortex. Acta Neuropathol 1996, 92(2):156-163.
-
(1996)
Acta Neuropathol
, vol.92
, Issue.2
, pp. 156-163
-
-
O'Kusky, J.R.1
Akers, M.A.2
Vinters, H.V.3
-
29
-
-
0036563399
-
Hemimegalencephaly: part 1. Genetic, clinical, and imaging aspects
-
[discussion 384]
-
Flores-Sarnat L. Hemimegalencephaly: part 1. Genetic, clinical, and imaging aspects. J Child Neurol 2002, 17(5):373-384. [discussion 384].
-
(2002)
J Child Neurol
, vol.17
, Issue.5
, pp. 373-384
-
-
Flores-Sarnat, L.1
-
30
-
-
84864402732
-
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
-
Lee J.H., Huynh M., Silhavy J.L., Kim S., Dixon-Salazar T., Heiberg A., et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 2012, 44(8):941-945.
-
(2012)
Nat Genet
, vol.44
, Issue.8
, pp. 941-945
-
-
Lee, J.H.1
Huynh, M.2
Silhavy, J.L.3
Kim, S.4
Dixon-Salazar, T.5
Heiberg, A.6
-
31
-
-
84855958205
-
MTOR: a pathogenic signaling pathway in developmental brain malformations
-
Crino P.B. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 2011, 17(12):734-742.
-
(2011)
Trends Mol Med
, vol.17
, Issue.12
, pp. 734-742
-
-
Crino, P.B.1
-
32
-
-
84877766754
-
Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder
-
182ra53
-
Parker W.E., Orlova K.A., Parker W.H., Birnbaum J.F., Krymskaya V.P., Goncharov D.A., et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med 2013, 5(182):182ra53.
-
(2013)
Sci Transl Med
, vol.5
, Issue.182
-
-
Parker, W.E.1
Orlova, K.A.2
Parker, W.H.3
Birnbaum, J.F.4
Krymskaya, V.P.5
Goncharov, D.A.6
-
33
-
-
34447637612
-
Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5
-
Puffenberger E.G., Strauss K.A., Ramsey K.E., Craig D.W., Stephan D.A., Robinson D.L., et al. Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5. Brain 2007, 130(Pt 7):1929-1941.
-
(2007)
Brain
, vol.130
, pp. 1929-1941
-
-
Puffenberger, E.G.1
Strauss, K.A.2
Ramsey, K.E.3
Craig, D.W.4
Stephan, D.A.5
Robinson, D.L.6
-
34
-
-
77951783390
-
STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice
-
Orlova K.A., Parker W.E., Heuer G.G., Tsai V., Yoon J., Baybis M., et al. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest 2010, 120(5):1591-1602.
-
(2010)
J Clin Invest
, vol.120
, Issue.5
, pp. 1591-1602
-
-
Orlova, K.A.1
Parker, W.E.2
Heuer, G.G.3
Tsai, V.4
Yoon, J.5
Baybis, M.6
-
35
-
-
84878352545
-
Mutations in DEPDC5 cause familial focal epilepsy with variable foci
-
Dibbens L.M., de Vries B., Donatello S., Heron S.E., Hodgson B.L., Chintawar S., et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013, 45(5):546-551.
-
(2013)
Nat Genet
, vol.45
, Issue.5
, pp. 546-551
-
-
Dibbens, L.M.1
de Vries, B.2
Donatello, S.3
Heron, S.E.4
Hodgson, B.L.5
Chintawar, S.6
-
36
-
-
84897110754
-
Epilepsy genetics revolutionizes clinical practice
-
Scheffer I.E. Epilepsy genetics revolutionizes clinical practice. Neuropediatrics 2014, 45(2):70-74.
-
(2014)
Neuropediatrics
, vol.45
, Issue.2
, pp. 70-74
-
-
Scheffer, I.E.1
-
37
-
-
84902273128
-
DEPDC5 mutations in genetic focal epilepsies of childhood
-
Lal D., Reinthaler E.M., Schubert J., Muhle H., Riesch E., Kluger G., et al. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann Neurol 2014, 75(5):788-792.
-
(2014)
Ann Neurol
, vol.75
, Issue.5
, pp. 788-792
-
-
Lal, D.1
Reinthaler, E.M.2
Schubert, J.3
Muhle, H.4
Riesch, E.5
Kluger, G.6
-
38
-
-
84902167691
-
DEPDC5 does it all: shared genetics for diverse epilepsy syndromes
-
Poduri A. DEPDC5 does it all: shared genetics for diverse epilepsy syndromes. Ann Neurol 2014, 75(5):631-633.
-
(2014)
Ann Neurol
, vol.75
, Issue.5
, pp. 631-633
-
-
Poduri, A.1
-
39
-
-
84902281810
-
Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations
-
Scheffer I.E., Heron S.E., Regan B.M., Mandelstam S., Crompton D.E., Hodgson B.L., et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol 2014, 75(5):782-787.
-
(2014)
Ann Neurol
, vol.75
, Issue.5
, pp. 782-787
-
-
Scheffer, I.E.1
Heron, S.E.2
Regan, B.M.3
Mandelstam, S.4
Crompton, D.E.5
Hodgson, B.L.6
-
40
-
-
84878357685
-
A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1
-
Bar-Peled L., Chantranupong L., Cherniack A.D., Chen W.W., Ottina K.A., Grabiner B.C., et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013, 340(6136):1100-1106.
-
(2013)
Science
, vol.340
, Issue.6136
, pp. 1100-1106
-
-
Bar-Peled, L.1
Chantranupong, L.2
Cherniack, A.D.3
Chen, W.W.4
Ottina, K.A.5
Grabiner, B.C.6
-
41
-
-
54549099013
-
PTEN hamartoma tumor syndromes
-
Blumenthal G.M., Dennis P.A. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008, 16(11):1289-1300.
-
(2008)
Eur J Hum Genet
, vol.16
, Issue.11
, pp. 1289-1300
-
-
Blumenthal, G.M.1
Dennis, P.A.2
-
42
-
-
84855985283
-
Lifetime cancer risks in individuals with germline PTEN mutations
-
Tan M.H., Mester J.L., Ngeow J., Rybicki L.A., Orloff M.S., Eng C., et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012, 18(2):400-407.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.2
, pp. 400-407
-
-
Tan, M.H.1
Mester, J.L.2
Ngeow, J.3
Rybicki, L.A.4
Orloff, M.S.5
Eng, C.6
-
43
-
-
85029461725
-
-
Lhermitte-Duclos disease in orphanet
-
Lhermitte-Duclos disease, in orphanet, 2006.
-
(2006)
-
-
-
44
-
-
52049126174
-
Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin
-
Squarize C.H., Castilho R.M., Gutkind J.S. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 2008, 68(17):7066-7072.
-
(2008)
Cancer Res
, vol.68
, Issue.17
, pp. 7066-7072
-
-
Squarize, C.H.1
Castilho, R.M.2
Gutkind, J.S.3
-
45
-
-
79958813923
-
Rapamycin treatment suppresses epileptogenic activity in conditional Pten knockout mice
-
D'Arcangelo G. Rapamycin treatment suppresses epileptogenic activity in conditional Pten knockout mice. Cell Cycle 2010, 9(13):2487-2488.
-
(2010)
Cell Cycle
, vol.9
, Issue.13
, pp. 2487-2488
-
-
D'Arcangelo, G.1
-
46
-
-
79958805057
-
Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation
-
Iacobas I., Burrows P.E., Adams D.M., Sutton V.R., Hollier L.H., Chintagumpala M.M. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer 2011, 57(2):321-323.
-
(2011)
Pediatr Blood Cancer
, vol.57
, Issue.2
, pp. 321-323
-
-
Iacobas, I.1
Burrows, P.E.2
Adams, D.M.3
Sutton, V.R.4
Hollier, L.H.5
Chintagumpala, M.M.6
-
47
-
-
84860389181
-
A mosaic activating mutation in AKT1 associated with the Proteus syndrome
-
Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M., Peters K., et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011, 365(7):611-619.
-
(2011)
N Engl J Med
, vol.365
, Issue.7
, pp. 611-619
-
-
Lindhurst, M.J.1
Sapp, J.C.2
Teer, J.K.3
Johnston, J.J.4
Finn, E.M.5
Peters, K.6
-
48
-
-
0036918288
-
Germline mutation of the tumour suppressor PTEN in Proteus syndrome
-
Smith J.M., Kirk E.P., Theodosopoulos G., Marshall G.M., Walker J., Rogers M., et al. Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet 2002, 39(12):937-940.
-
(2002)
J Med Genet
, vol.39
, Issue.12
, pp. 937-940
-
-
Smith, J.M.1
Kirk, E.P.2
Theodosopoulos, G.3
Marshall, G.M.4
Walker, J.5
Rogers, M.6
-
49
-
-
0035928416
-
Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes
-
Zhou X., Hampel H., Thiele H., Gorlin R.J., Hennekam R.C., Parisi M., et al. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001, 358(9277):210-211.
-
(2001)
Lancet
, vol.358
, Issue.9277
, pp. 210-211
-
-
Zhou, X.1
Hampel, H.2
Thiele, H.3
Gorlin, R.J.4
Hennekam, R.C.5
Parisi, M.6
-
50
-
-
0035895042
-
PTEN mutations and proteus syndrome
-
Biesecker L.G., Rosenberg M.J., Vacha S., Turner J.T., Cohen M.M. PTEN mutations and proteus syndrome. Lancet 2001, 358(9298):2079-2080.
-
(2001)
Lancet
, vol.358
, Issue.9298
, pp. 2079-2080
-
-
Biesecker, L.G.1
Rosenberg, M.J.2
Vacha, S.3
Turner, J.T.4
Cohen, M.M.5
-
51
-
-
80055087787
-
An activating mutation of AKT2 and human hypoglycemia
-
Hussain K., Challis B., Rocha N., Payne F., Minic M., Thompson A., et al. An activating mutation of AKT2 and human hypoglycemia. Science 2011, 334(6055):474.
-
(2011)
Science
, vol.334
, Issue.6055
, pp. 474
-
-
Hussain, K.1
Challis, B.2
Rocha, N.3
Payne, F.4
Minic, M.5
Thompson, A.6
-
52
-
-
44649203072
-
Rapamycin treatment for a child with germline PTEN mutation
-
Marsh D.J., Trahair T.N., Martin J.L., Chee W.Y., Walker J., Kirk E.P., et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008, 5(6):357-361.
-
(2008)
Nat Clin Pract Oncol
, vol.5
, Issue.6
, pp. 357-361
-
-
Marsh, D.J.1
Trahair, T.N.2
Martin, J.L.3
Chee, W.Y.4
Walker, J.5
Kirk, E.P.6
-
53
-
-
84884469901
-
Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review)
-
Banno K., Kisu I., Yanokura M., Masuda K., Ueki A., Kobayashi Y., et al. Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review). Oncol Lett 2013, 6(5):1184-1188.
-
(2013)
Oncol Lett
, vol.6
, Issue.5
, pp. 1184-1188
-
-
Banno, K.1
Kisu, I.2
Yanokura, M.3
Masuda, K.4
Ueki, A.5
Kobayashi, Y.6
-
54
-
-
77953985258
-
Peutz-Jeghers syndrome: a systematic review and recommendations for management
-
Beggs A.D., Latchford A.R., Vasen H.F., Moslein G., Alonso A., Aretz S., et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010, 59(7):975-986.
-
(2010)
Gut
, vol.59
, Issue.7
, pp. 975-986
-
-
Beggs, A.D.1
Latchford, A.R.2
Vasen, H.F.3
Moslein, G.4
Alonso, A.5
Aretz, S.6
-
55
-
-
3142594193
-
The LKB1 tumor suppressor negatively regulates mTOR signaling
-
Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6(1):91-99.
-
(2004)
Cancer Cell
, vol.6
, Issue.1
, pp. 91-99
-
-
Shaw, R.J.1
Bardeesy, N.2
Manning, B.D.3
Lopez, L.4
Kosmatka, M.5
DePinho, R.A.6
-
56
-
-
12144287284
-
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1
-
Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004, 23(4):833-843.
-
(2004)
EMBO J
, vol.23
, Issue.4
, pp. 833-843
-
-
Lizcano, J.M.1
Goransson, O.2
Toth, R.3
Deak, M.4
Morrice, N.A.5
Boudeau, J.6
-
57
-
-
84907994949
-
AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease
-
Grahame Hardie D. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med 2014, DOI: 10.1111/joim.12268.
-
(2014)
J Intern Med
-
-
Grahame Hardie, D.1
-
58
-
-
84865955793
-
Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies
-
Kushwaha S., Xu X. Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies. Trends Cardiovasc Med 2012, 22(2):39-43.
-
(2012)
Trends Cardiovasc Med
, vol.22
, Issue.2
, pp. 39-43
-
-
Kushwaha, S.1
Xu, X.2
-
59
-
-
84862129718
-
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome
-
Kurek K.C., Luks V.L., Ayturk U.M., Alomari A.I., Fishman S.J., Spencer S.A., et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 2012, 90(6):1108-1115.
-
(2012)
Am J Hum Genet
, vol.90
, Issue.6
, pp. 1108-1115
-
-
Kurek, K.C.1
Luks, V.L.2
Ayturk, U.M.3
Alomari, A.I.4
Fishman, S.J.5
Spencer, S.A.6
-
60
-
-
84856219440
-
Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis
-
Mirzaa G.M., Conway R.L., Gripp K.W., Lerman-Sagie T., Siegel D.H., deVries L.S., et al. Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. Am J Med Genet A 2012, 158A(2):269-291.
-
(2012)
Am J Med Genet A
, vol.158 A
, Issue.2
, pp. 269-291
-
-
Mirzaa, G.M.1
Conway, R.L.2
Gripp, K.W.3
Lerman-Sagie, T.4
Siegel, D.H.5
deVries, L.S.6
-
61
-
-
84876806696
-
Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP
-
Mirzaa G.M., Riviere J.B., Dobyns W.B. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP. Am J Med Genet C Semin Med Genet 2013, 163C(2):122-130.
-
(2013)
Am J Med Genet C Semin Med Genet
, vol.163 C
, Issue.2
, pp. 122-130
-
-
Mirzaa, G.M.1
Riviere, J.B.2
Dobyns, W.B.3
-
62
-
-
84899650142
-
De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome
-
Mirzaa G.M., Parry D.A., Fry A.E., Giamanco K.A., Schwartzentruber J., Vanstone M., et al. De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome. Nat Genet 2014, 46(5):510-515.
-
(2014)
Nat Genet
, vol.46
, Issue.5
, pp. 510-515
-
-
Mirzaa, G.M.1
Parry, D.A.2
Fry, A.E.3
Giamanco, K.A.4
Schwartzentruber, J.5
Vanstone, M.6
-
63
-
-
37549016789
-
Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation
-
Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia 2008, 49(1):8-21.
-
(2008)
Epilepsia
, vol.49
, Issue.1
, pp. 8-21
-
-
Wong, M.1
-
64
-
-
84875716234
-
Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin
-
Yang J., Kalogerou M., Gallacher J., Sampson J.R., Shen M.H. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. Eur J Cancer 2013, 49(6):1479-1490.
-
(2013)
Eur J Cancer
, vol.49
, Issue.6
, pp. 1479-1490
-
-
Yang, J.1
Kalogerou, M.2
Gallacher, J.3
Sampson, J.R.4
Shen, M.H.5
-
65
-
-
84857416727
-
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC)
-
Auricchio N., Malinowska I., Shaw R., Manning B.D., Kwiatkowski D.J. Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). PLoS ONE 2012, 7(2):e31900.
-
(2012)
PLoS ONE
, vol.7
, Issue.2
, pp. e31900
-
-
Auricchio, N.1
Malinowska, I.2
Shaw, R.3
Manning, B.D.4
Kwiatkowski, D.J.5
-
66
-
-
84896401739
-
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
-
Polivka J., Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2014, 142(2):164-175.
-
(2014)
Pharmacol Ther
, vol.142
, Issue.2
, pp. 164-175
-
-
Polivka, J.1
Janku, F.2
|